Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer treatment, yet up to 30% of men experience significant long-term side effects affecting physical, metabolic, and psychological wellbeing. While there is strong evidence supporting exercise, lifestyle, and psychosocial interventions, access to coordinated support remains inconsistent across services.
Join us to explore LiveWell — our new innovative, evidence-based virtual support platform within the Infopool — designed to provide personalised exercise, lifestyle and psychosocial interventions for men receiving hormone therapy. This webinar will highlight the need for improved support, the development of LiveWell, and its potential to improve patient outcomes and support both patients and healthcare delivery.
During this webinar we will explore:
- The challenges patients experience while receiving hormone therapy and the need for improved support pathways
- The new LiveWell service — what it is, how it was developed and how it supports personalised patient care
- The role of in-house personalised digital tools and AI-enhanced support in expanding access to wellbeing support and self-management
- A patient perspective on living with hormone therapy and the role of services like LiveWell.
Who should attend:
Healthcare professionals involved in the care of men affected by prostate cancer (including oncology, urology, nursing, psychology, and allied healthcare professionals).
Agenda
- 6:00pm - Welcome, Housekeeping & Introductions
Chair: Pauline Bagnall, CNS PCR - 6:05pm ‘Reimagining Support for Men Living on Hormone Therapy: A Digital Rehabilitation Solution’
Louisa Fleure Urology Consultant Nurse. Guy’s & St Thomas’ NHS Foundation Trust, London and PCR Trustee - 6.30pm ‘Supporting Life With and Beyond Prostate Cancer: Introducing the LiveWell Virtual Wellbeing Service’
Dr Sara Nelson Head of Health Information at PCR - 6:50pm ‘Understanding the Challenges of Hormone Therapy and How the New LiveWell Service Can Help’
Andy Keen Patient Representative - 7:00pm Q&A session
- 7:15pm Closing remarks
